Patents Assigned to ITERION THERAPEUTICS, INC.
  • Formulations of tegavivint
    Patent number: 11964054
    Abstract: Formulations of tegavivint, methods of making such formulations, and methods of treatment of cancer by administering the formulations.
    Type: Grant
    Filed: February 6, 2023
    Date of Patent: April 23, 2024
    Assignee: Iterion Therapeutics, Inc.
    Inventors: Gowri Sukumar, Drazen Ostovic
  • Lyophilized formulations of tegavivint
    Patent number: 11793759
    Abstract: Lyophilized formulations of tegavivint, methods of making such formulations, and methods of treatment of cancer by administering the formulations.
    Type: Grant
    Filed: June 23, 2021
    Date of Patent: October 24, 2023
    Assignee: ITERION THERAPEUTICS, INC.
    Inventors: Gowri Sukumar, Drazen Ostovic
  • Lyophilized formulations of tegavivint
    Patent number: 11602501
    Abstract: Lyophilized formulations of tegavivint, methods of making such formulations, and methods of treatment of cancer by administering the formulations.
    Type: Grant
    Filed: October 4, 2021
    Date of Patent: March 14, 2023
    Assignee: Iterion Therapeutics, Inc.
    Inventors: Gowri Sukumar, Drazen Ostovic
  • Lyophilized formulations of tegavivint
    Patent number: 11571388
    Abstract: Lyophilized formulations of tegavivint, methods of making such formulations, and methods of treatment of cancer by administering the formulations.
    Type: Grant
    Filed: November 24, 2020
    Date of Patent: February 7, 2023
    Assignee: Iterion Therapeutics, Inc.
    Inventors: Gowri Sukumar, Drazen Ostovic
  • Crystalline form of tegavivint, method of preparation, and use thereof
    Patent number: 11136307
    Abstract: The present invention relates to crystalline forms of (9E,10E)-2,7-bis((3,5-dimethylpiperidin-1-yl)sulfonyl)anthracene-9,10-dione dioxime, pharmaceutical compositions comprising the crystalline form, processes for preparing the crystalline form and methods of use therefore.
    Type: Grant
    Filed: September 29, 2020
    Date of Patent: October 5, 2021
    Assignee: ITERION THERAPEUTICS, INC.
    Inventors: Drazen Ostovic, Gowri Sukumar